No matches

Educational Resources

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

Pulmonology

5 min

interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

Dermatology

23 min

Podcast

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Pulmonology

19 min

expert video

Barrier disruption in AD and the development of environmental and food allergies

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

Rhinology

9 min

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Rhinology

9 min

expert video

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ESPGHAN 2024 | Shedding Light on Pediatric Eosinophilic Esophagitis: Timely Identification and Management

Gastroenterology

35 min

expert video

ESPGHAN 2024 | Shedding Light on Pediatric Eosinophilic Esophagitis: Timely Identification and Management

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Dermatology

20 min

Podcast

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region

Educational Resources

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

What Are the Key Inflammatory Processes in Patients with COPD?

What do we mean by disease control in AD?

CRSwNP: A Chronic Type 2 Inflammatory Disease

Barrier disruption in AD and the development of environmental and food allergies

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ESPGHAN 2024 | Shedding Light on Pediatric Eosinophilic Esophagitis: Timely Identification and Management

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Educational Resources

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

What Are the Key Inflammatory Processes in Patients with COPD?

What do we mean by disease control in AD?

CRSwNP: A Chronic Type 2 Inflammatory Disease

Barrier disruption in AD and the development of environmental and food allergies

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ESPGHAN 2024 | Shedding Light on Pediatric Eosinophilic Esophagitis: Timely Identification and Management

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?